Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy.
Piekarz, Richard L. MD, PhD *; Sackett, Dan L. PhD +; Bates, Susan E. MD *
13(1):30-39, January/February 2007.
(Format: HTML, PDF)
The histone deacetylase inhibitors are a new class of agents that are currently in various stages of clinical development. Clinical trials have demonstrated activity, urging further investigation. At the same time, it has been discovered that these agents have their own challenges. In this review, we discuss clinical data gathered to date, combination therapies designed to increase efficacy, and toxicities attributed to this new class of agents.
(C) 2007 Lippincott Williams & Wilkins, Inc.